(ANSA-XINHUA) - BEJING, MAY 27 - Two inactivated vaccines
developed by the Chinese pharmaceutical giant Sinopharm have
shown to be safe and effective against COVID-19 in phase-3 human
trials, according to a study published this week in The Journal
of the American Medical Association. The randomized,
double-blind and placebo-controlled trials were designed by the
Wuhan Institute of Biological Products Co, Ltd, and the Beijing
Institute of Biological Products Co, Ltd, both of which belong
to the China National Biotec Group(CNBG), affiliated with
Sinopharm. It is the world's first published phase-3 study
results of inactivated COVID-19 vaccines, the CNBG said in a
statement on Thursday. According to the study, more than 40,000
people overseas aged 18 and above were enrolled in the trials.
The vaccination procedure included two shots with an interval of
21 days. The virus strains in the study were isolated from two
patients in Wuhan's designated coronavirus-treating Jinyintan
Hospital and separately used to develop the two inactivated
vaccines. Fourteen days after inoculation, all vaccine receivers
produced high titers of antibodies, and the seroconversion rate
of neutralizing antibodies was higher than 99 percent in both
vaccine groups, indicating strong immune responses induced by
the two vaccines, the study said (ANSA-XINHUA).
© Copyright ANSA - All rights reserved